STOCK TITAN

ERPY - ERPY STOCK NEWS

Welcome to our dedicated page for ERPY news (Ticker: ERPY), a resource for investors and traders seeking the latest updates and insights on ERPY stock.

ERP Technologies (ERPY) provides investors and business professionals with essential updates through this comprehensive news hub. Track official announcements including financial disclosures, product enhancements, and strategic collaborations that shape this ERP innovator's market position.

Access timely updates on earnings reports, operational milestones, and partnership developments like ERPY's collaboration with Vetophage. Our curated feed ensures you never miss critical information about software innovations or industry leadership changes.

Discover verified information about enterprise solution developments directly from primary sources. This resource serves both technical professionals seeking product details and investors monitoring organizational growth patterns.

Bookmark this page for streamlined access to ERPY's evolving business narrative. Regular updates ensure you maintain informed perspectives on this dynamic player in enterprise resource planning technology.

Rhea-AI Summary
PHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strains.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
PHAXIAM has regained compliance with Nasdaq Listing Rule 5550(a)(2) after its closing bid price of American Depositary Shares (ADSs) remained above $1.00 per ADS for 10 consecutive business days from September 18 to September 29, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
PHAXIAM Therapeutics and Vetophage announce strategic research collaboration in the fight against antimicrobial resistance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
PHAXIAM provides business and financial update for the first half of 2023. Formation of PHAXIAM Therapeutics to create a global leader in phage therapies. Plan to launch new phase 2b/3 study in Prosthetic Joint Infections. Cash and cash equivalents of €25.2 million ($27.5 million) as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive bacterial target
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
PHAXIAM Therapeutics completes reverse share split, exchanging 10 existing shares for 1 new share. New shares listed on Euronext Paris. ADR holders required to exchange old ADSs for new ADSs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Monthly information related to total number of voting rights and shares composing the share capital as of August 31, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
PHAXIAM Therapeutics publishes cash position & financial calendar, announces participation at investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
ERPY

Nasdaq:ERPY

ERPY Rankings

ERPY Stock Data